Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GK NAM is a small molecule negative allosteric modulator of glucokinase (GK) currently in early-stage development by Hua Medicine. Glucokinase acts as a critical glucose sensor in the liver and pancreatic beta cells, regulating insulin secretion and glucose metabolism. While glucokinase activators (GKAs) like dorzagliatin are used to treat type 2 diabetes, negative allosteric modulators (NAMs) are designed to reduce the enzyme's activity or sensitivity. This mechanism is primarily investigated for the treatment of metabolic conditions characterized by hyperinsulinemia and hypoglycemia, such as congenital hyperinsulinism (CHI) or persistent hyperinsulinemic hypoglycemia of infancy (PHHI), where overactive glucokinase leads to excessive insulin secretion. GK NAM is part of Hua Medicine's broader pipeline focused on maintaining glucose homeostasis and metabolic health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GK NAM.